---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-022"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: ESK-001-022. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 2 further headings. 12 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence/esk-001-022"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: ESK-001-022

<a id="heading-3.1.10"></a>

## 3.1.10 ESK-001-022

<a id="heading-3.1.10.1"></a>

### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

#### Brief summary in the ClinicalTrials.gov record

> “This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.2"></a>

### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

#### Study start and completion dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-04-29”
> “Primary Completion (Actual) 2026-03-24”
> “Study Completion (Actual) 2026-03-24”
> “First Posted 2025-05-01”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="topic-3.1.10.2-2"></a>

#### Completion dates estimated at registration, April 2025, superseded in May 2026

> “Primary Completion 2025-12 [Estimated]”
> “Study Completion 2025-12 [Estimated]”

Source: [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)

<a id="topic-3.1.10.2-3"></a>

#### Sites in California, Florida, and Tennessee in the ClinicalTrials.gov record

> “This study has 4 locations”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

| Site | Quoted record |
| --- | --- |
| California | “Lake Forest, California, United States, 92630” |
| Florida | “Miami Lakes, Florida, United States, 33104” |
| Florida | “Orlando, Florida, United States, 32809” |
| Tennessee | “Knoxville, Tennessee, United States, 37920” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="topic-3.1.10.2-4"></a>

#### Recruitment and results status in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2026-05-12” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.3"></a>

### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

#### Official title and design details in the ClinicalTrials.gov record

> “A Phase 1, Open Label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of ESK001”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

| Field | Quoted record |
| --- | --- |
| Other study ID numbers | “ESK-001-022” |
| Conditions | “Hepatic Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.4"></a>

### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

#### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

| Criterion | Quoted record |
| --- | --- |
| Inclusion, all participants | “Body mass index between 18.0 and 40.0 kg/m2” |
| Inclusion, hepatic impairment | “Diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant changes within 30 days prior to dosing, as determined by medical history” |
| Exclusion, all participants | “Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 105 mmHg), or uncontrolled treated/untreated hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg), or resting pulse rate < 45 or > 100 bpm.” |
| Exclusion, healthy volunteers | “Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator or designee.” |
| Exclusion, healthy volunteers | “Positive hepatitis panel and/or positive human immunodeficiency virus test.” |
| Exclusion, hepatic impairment | “History of any uncontrolled or unstable renal, hematological, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator or designee, within 6 months prior to screening.” |
| Exclusion, hepatic impairment | “History or current diagnosis of uncontrolled or significant cardiac disease indicative of a significant risk of safety for participation in the study.” |
| Exclusion, hepatic impairment | “Liver function tests outside the appropriate reference ranges that are not consistent with hepatic dysfunction, as determined by the investigator or designee.” |
| Exclusion, hepatic impairment | “QTcF > 480 ms for males or > 490 ms for females at screening or check-in, as confirmed from the mean of the original value and 2 repeats.” |
| Ages eligible for study | “18 Years to 75 Years (Adult, Older Adult )” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.5"></a>

### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Arm description |
| --- | --- |
| “Experimental: Healthy Volunteer” | “Up to 24 healthy volunteer participants will receive a single dose of ESK-001” |
| “Experimental: Mild Hepatic Impairment” | “8 participants with mild hepatic impairment will receive a single dose of ESK-001” |
| “Experimental: Moderate Hepatic Impairment” | “8 participants with moderate hepatic impairment will receive a single dose of ESK-001” |
| “Experimental: Severe Hepatic Impairment” | “8 participants with severe hepatic impairment will receive a single dose of ESK-001” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.6"></a>

### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

#### 3.1.10.6.1 Rationale for Using Pharmacokinetic Parameters as the Primary Endpoint

<a id="topic-3.1.10.6.1-1"></a>

##### Primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum observed plasma concentration (Cmax)” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]” | “48 hours” |
| Primary | “Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]” | “48 hours” |
| Secondary | “Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation” | “48 hours” |
| Secondary | “Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations” | “48 hours” |

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="heading-3.1.10.7"></a>

### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

#### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 32”

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634)

<a id="topic-3.1.10.7.1-2"></a>

##### Enrollment estimated at registration, April 2025, superseded in May 2026

> “Enrollment 48 [Estimated]”

Source: [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)

<a id="heading-3.1.10.7.2"></a>

#### 3.1.10.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.10.8"></a>

### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

#### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

#### 3.1.10.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.10.8.3"></a>

#### 3.1.10.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.10.8.4"></a>

#### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.10.8.5"></a>

#### 3.1.10.8.5 Safety Results

No evidence found.

<a id="heading-3.1.10.9"></a>

### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

#### Summary

- The hepatic impairment study has no posted results, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- The design is open-label and non-randomized, with one dose of ESK-001 of unstated strength and a 48-hour outcome time frame.
- Actual enrollment was 32 participants, against 48 estimated at registration and a planned structure of up to 24 healthy volunteers and 8 participants each with mild, moderate, and severe hepatic impairment; the number enrolled in each group is not reported.

Source: [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634); [ClinicalTrials.gov NCT06952634 version 1](https://clinicaltrials.gov/study/NCT06952634?tab=history&a=1)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
